Group 1: Investment Opportunities in Tourism and CRO Industry - Mid-term focus on companies in the tourism service sector such as China Youth Travel Service, China Duty Free Group, Songcheng Performance, and Jinjiang Hotels, especially those targeting mid-to-high-end tourism consumption and high-growth regions like East and South China [1] - The domestic CRO industry has transitioned from a boom driven by policy and capital to a downturn dominated by oversupply and shrinking demand, indicating a clear mid-to-long-term investment logic due to policy catalysts and concentration among leading firms [3] - For investors with higher risk tolerance, the current period may present a left-side opportunity to invest in quality CRO companies, with a recommendation to closely monitor policy developments and changes in the fundamentals of leading firms [3] Group 2: Trends in Livestock and New Energy Vehicles - Short-term caution against heavily investing in pig farming stocks such as Wens Foodstuffs, Muyuan Foods, and Zhengbang Technology, as profitability remains challenged [3] - The pig industry is currently experiencing a phase of high prices stagnating, rising costs, and cautious restocking, leading to compressed profits across the industry chain, which is unfavorable for the recovery of farming profitability [3] - Data indicates a significant increase in the acceptance of new energy vehicles for long-distance travel, suggesting a structural change in user behavior beyond urban commuting [2] Group 3: Developments in Pharmaceutical Retail - The launch of the first national standard for research-oriented pharmacies marks a significant step in integrating pharmacies into the clinical research system, enhancing the diversity and validity of data samples for traditional Chinese medicine [6][7] - Major chain pharmacies like Yifeng Pharmacy, Dazhenglin, and Lao Baixing are expected to lead the transformation into research-oriented pharmacies, equipped with necessary data collection devices and quality control systems [7] - Traditional Chinese medicine companies such as Tongrentang, Yunnan Baiyao, Yiling Pharmaceutical, and Kangyuan Pharmaceutical may benefit from this new model by expanding real-world data channels and improving the success rate of new drug registrations [6]